Phenotypes associated with this allele

• Allele Symbol: Tg(Ins1-cre/ERT)1Lphi
• Allele Name: transgene insertion 1, Louis Philipson
• Allele ID: MGI:4410453
• Summary: 4 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Gt(ROSA)26Sor^tm1(Cacna1c*)Red/Gt(ROSA)26Sor^+ Tg(Ins1-cre/ERT)1Lphi/0	involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * CD-1	MGI:8266442
cn2	Ier3ip1^tm1Arvn/Ier3ip1^tm1Arvn Tg(Ins1-cre/ERT)1Lphi/0	involves: 129S4/SvJaeSor * C57BL/6J * CD-1	MGI:7620431
cn3	Gck^tm1Ydor/Gck^+ Tg(Ins1-cre/ERT)1Lphi/0	involves: C57BL/6 * C57BL/6J * CD-1	MGI:6690684
cn4	Abhd6^tm1c(EUCOMM)Hmgu/Abhd6^tm1c(EUCOMM)Hmgu Tg(Ins1-cre/ERT)1Lphi/0	involves: C57BL/6N * CD-1	MGI:6276028

Genotype
MGI:8266442

cn1

• Allelic Composition: Gt(ROSA)26Sor^{tm1(Cacna1c*)Red}/Gt(ROSA)26Sor⁺; Tg(Ins1-cre/ERT)1Lphi/0
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * CD-1

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

homeostasis/metabolism

homeostasis/metabolism phenotype ( J:361120 )

♂N • in a glucose tolerance test, tamoxifen-treated mice show no differences in basal blood glucose or after an i.p. glucose bolus compared to controls

Genotype
MGI:7620431

cn2

• Allelic Composition: Ier3ip1^tm1Arvn/Ier3ip1^tm1Arvn; Tg(Ins1-cre/ERT)1Lphi/0
• Genetic Background: involves: 129S4/SvJaeSor * C57BL/6J * CD-1

homeostasis/metabolism

abnormal glucose homeostasis ( J:336782 )

♂ • male mice treated with tamoxifen at 8 weeks of age (to induce IER3IP1 deletion in beta cells in early adulthood) develop a diabetic phenotype

decreased insulin secretion ( J:336782 )

♂ • adult male mice show a reduction of proinsulin and insulin content in pancreatic islets at 2 and 4 weeks after tamoxifen injection

hyperglycemia ( J:336782 )

♂ • adult mice show persistent hyperglycemia at 4 weeks after tamoxifen injection

decreased circulating insulin level ( J:336782 )

♂ • adult mice show decreased serum insulin levels at 4 weeks after tamoxifen injection

impaired glucose tolerance ( J:336782 )

♂ • adult mice show significantly higher blood glucose levels than control littermates at all time points tested in oral glucose tolerance tests starting from 2 weeks after tamoxifen injection

endocrine/exocrine glands

increased pancreatic beta cell apoptosis ( J:336782 )

♂ • pancreatic islets show significantly increased mRNA levels of Trib3 (a mediator of ER stress-induced cell death) at 4 weeks after tamoxifen injection

♂ • in contrast, mRNA levels of the antiapoptotic gene Bcl2 are significantly suppressed

decreased pancreatic beta cell proliferation ( J:336782 )

♂ • pancreatic islets show significantly increased mRNA levels of the cell growth inhibitor p21/Cdkn1a at 4 weeks after tamoxifen injection

abnormal pancreatic beta cell morphology ( J:336782 )

♂ • adult male mice show a more-diffuse cytoplasmic distribution of proinsulin and increased Pro+/Ins-cells at 4 weeks after tamoxifen injection

abnormal pancreatic beta cell differentiation ( J:336782 )

♂ • pancreatic islets of adult male mice show significantly reduced mRNA levels of beta-cell transcription factors both at 2 weeks (Mafa) and at 4 weeks (Mafa, Pdx1, and Nkx6-1) after tamoxifen injection, along with decreases in PDX1 and NKX6-1 protein levels at 4 weeks post-injection

decreased insulin secretion ( J:336782 )

♂ • adult male mice show a reduction of proinsulin and insulin content in pancreatic islets at 2 and 4 weeks after tamoxifen injection

cellular

increased pancreatic beta cell apoptosis ( J:336782 )

♂ • pancreatic islets show significantly increased mRNA levels of Trib3 (a mediator of ER stress-induced cell death) at 4 weeks after tamoxifen injection

♂ • in contrast, mRNA levels of the antiapoptotic gene Bcl2 are significantly suppressed

abnormal pancreatic beta cell differentiation ( J:336782 )

♂ • pancreatic islets of adult male mice show significantly reduced mRNA levels of beta-cell transcription factors both at 2 weeks (Mafa) and at 4 weeks (Mafa, Pdx1, and Nkx6-1) after tamoxifen injection, along with decreases in PDX1 and NKX6-1 protein levels at 4 weeks post-injection

decreased pancreatic beta cell proliferation ( J:336782 )

♂ • pancreatic islets show significantly increased mRNA levels of the cell growth inhibitor p21/Cdkn1a at 4 weeks after tamoxifen injection

Genotype
MGI:6690684

cn3

• Allelic Composition: Gck^tm1Ydor/Gck⁺; Tg(Ins1-cre/ERT)1Lphi/0
• Genetic Background: involves: C57BL/6 * C57BL/6J * CD-1

homeostasis/metabolism

hypoglycemia ( J:302600 )

• mice treated with tamoxifen exhibit long-term, persistent hypoglycemia

impaired glucose tolerance ( J:302600 )

• 9-month-old tamoxifen-treated mice, but not 1.5-month-old tamoxifen-treated mice, exhibit abnormal glucose tolerance

endocrine/exocrine glands

increased pancreatic beta cell mass ( J:302600 )

• tamoxifen-treated mice exhibit an increase in beta cell mass at 1.5 months of age, but this increase is no longer seen at 9 months of age

Genotype
MGI:6276028

cn4

• Allelic Composition: Abhd6^{tm1c(EUCOMM)Hmgu}/Abhd6^{tm1c(EUCOMM)Hmgu}; Tg(Ins1-cre/ERT)1Lphi/0
• Genetic Background: involves: C57BL/6N * CD-1
• Cell Lines: HEPD0651_8_C07

endocrine/exocrine glands

increased insulin secretion ( J:215257 )

• islets from tamoxifen-treated mice show enhanced glucose-stimulated insulin secretion

• however, tamoxifen treated mice show normal body weight, food intake and no changes in beta cell mass

homeostasis/metabolism

increased insulin secretion ( J:215257 )

• islets from tamoxifen-treated mice show enhanced glucose-stimulated insulin secretion

• however, tamoxifen treated mice show normal body weight, food intake and no changes in beta cell mass

increased circulating insulin level ( J:215257 )

• tamoxifen-treated males show elevated insulinemia during oral glucose tolerance test

improved glucose tolerance ( J:215257 )

• tamoxifen-treated males show slightly improved glucose tolerance during oral glucose tolerance test